Cargando…

Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case

Detalles Bibliográficos
Autor principal:	Yuasa, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057742/ https://www.ncbi.nlm.nih.gov/pubmed/35509790 http://dx.doi.org/10.1002/iju5.12428

Ejemplares similares

Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
por: Kirishima, Fumiaki, et al.
Publicado: (2022)

Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
por: Zang, Zhijiang, et al.
Publicado: (2022)

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
por: De Santis, Maria, et al.
Publicado: (2019)

Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2020)

Editorial Comment to Castration‐resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy
por: Pennuto, Maria, et al.
Publicado: (2022)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Editorial Comment to A case of steroid‐resistant cystitis as an immune‐related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab
por: Yuasa, Takeshi
Publicado: (2022)

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
por: Alkhudair, Nora A.
Publicado: (2019)

Editorial Comment to Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report
por: Yamamoto, Yoshiyuki
Publicado: (2019)

Editorial Comment to Testicular metastasis from urothelial carcinoma of the bladder
por: Yuasa, Takeshi
Publicado: (2021)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Editorial Comment to Cystic partially differentiated nephroblastoma in a 74‐year‐old patient
por: Yuasa, Takeshi
Publicado: (2021)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Editorial Comment to A case of adenocarcinoma of the rete testis with durable response to cisplatin‐based chemotherapy
por: Yuasa, Takeshi
Publicado: (2021)

Editorial Comment to Syndrome of inappropriate antidiuretic hormone secretion as a side effect of chemotherapy for testicular cancer: A case report
por: Yuasa, Takeshi
Publicado: (2019)

Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma
por: Yuasa, Takeshi
Publicado: (2020)

Editorial Comment from Dr Hamidi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Hamidi, Nurullah
Publicado: (2021)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Editorial Comment to Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors
por: Yuasa, Takeshi
Publicado: (2019)

Editorial Comment from Dr Yuasa to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Yuasa, Takeshi
Publicado: (2020)

Editorial Comment to Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Yuasa, Takeshi
Publicado: (2021)

Editorial Comment from Dr Hirayama and Dr Iguchi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Editorial Comment: Translational research in urology: nutricion and prostate
por: Favorito, Luciano A.
Publicado: (2021)

Editorial Comment to Granulomatous prostatitis with high suspicion of prostatic adenocarcinoma on radiological imaging
por: Sekito, Takanori, et al.
Publicado: (2021)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

Editorial Comment
por: Madbouly, Khaled
Publicado: (2011)

EDITORIAL COMMENT
por: Mladenov, Dimitar
Publicado: (2013)

EDITORIAL COMMENT
por: Gibas, Artur
Publicado: (2013)

EDITORIAL COMMENT
por: Salagierski, Maciej
Publicado: (2013)

EDITORIAL COMMENT
por: Tiu, Albert, et al.
Publicado: (2013)

EDITORIAL COMMENT
por: Poletajew, Sławomir, et al.
Publicado: (2013)

EDITORIAL COMMENT
por: Oszukowska, Elżbieta
Publicado: (2013)

EDITORIAL COMMENT
por: Matuszewski, Marcin
Publicado: (2013)

EDITORIAL COMMENT
por: Świniarski, Piotr Paweł
Publicado: (2013)

EDITORIAL COMMENT
por: Apoznański, Wojciech
Publicado: (2013)

Editorial Comment
por: Goel, Apul
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_55ek541gkv5kmrsruk29voc4u2